Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases

Seminars in Immunology

Volumn 34, Issue , 2017, Pages 61-67

  Prosperi, Davide ^a   Colombo, Miriam ^a   Zanoni, Ivan ^a,b   Granucci, Francesca ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Autoimmune diseases; Dendritic cells; Inflammatory diseases; Innate immune cells; Macrophages; Nanomedicine; Nanoparticles

Indexed keywords

NANOCARRIER; NANOPARTICLE;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE CONTROL; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; CHEMISTRY; COLLOID; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; METABOLISM; MONONUCLEAR PHAGOCYTE; NEUTROPHIL; PHAGOCYTOSIS;

AUTOIMMUNITY; COLLOIDS; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; MACROPHAGES; MONONUCLEAR PHAGOCYTE SYSTEM; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEUTROPHILS; PHAGOCYTOSIS;

EID: 85028365308     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2017.08.010     Document Type: Review

References (79)

1. Ferrari, M., Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5 (2005), 161–171.
2. Clemente-Casares, X., Santamaria, P., Nanomedicine in autoimmunity. Immunol. Lett. 158 (2014), 167–174.
3. Xia, Y., Editorial: are we entering the nano era?. Angew. Chem. Int. Ed. Engl. 53 (2014), 12268–12271.
4. Eifler, A.C., Thaxton, C.S., Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol. Biol. 726 (2011), 325–338.
5. Davis, M.E., Chen, Z.G., Shin, D.M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7 (2008), 771–782.
6. Sun, T., Zhang, Y.S., Pang, B., Hyun, D.C., Yang, M., Xia, Y., Engineered NPs for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53 (2014), 12320–12364.
7. Brunner, T., Cohen, S., Monsonego, A., Silencing of proinflammatory genes targeted to peritoneal-residing macrophages using siRNA encapsulated in biodegradable microspheres. Biomaterials 31 (2010), 2627–2636.
8. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Release 125 (2008), 193–209.
9. Khoury, M., Escriou, V., Courties, G., Galy, A., Yao, R., Largeau, C., Scherman, D., Jorgensen, C., Apparailly, F., Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 58 (2008), 2356–2367.
10. Moon, J.J., Huang, B., Irvine, D.J., Engineering nano- and microparticles to tune immunity. Adv. Mater. 24 (2012), 3724–3746.
11. Puri, A., Loomis, K., Smith, B., Lee, J.H., Yavlovich, A., Heldman, E., Blumenthal, R., Lipid-based NPs as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26 (2009), 523–580.
12. Yeste, A., Takenaka, M.C., Mascanfroni, I.D., Nadeau, M., Kenison, J.E., Patel, B., Tukpah, A.M., Babon, J.A., DeNicola, M., Kent, S.C., Pozo, D., Quintana, F.J., Tolerogenic NPs inhibit t cell-mediated autoimmunity through SOCS2. Sci. Signal., 9, 2016, ra61.
13. Hayter, S.M., Cook, M.C., Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun. Rev. 11 (2012), 754–765.
14. Janeway, C.A. Jr., Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54:Pt. 1 (1989), 1–13.
15. Brubaker, S.W., Bonham, K.S., Zanoni, I., Kagan, J.C., Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 33 (2015), 257–290.
16. Metcalfe, S.M., Fahmy, T.M., Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol. Med. 18 (2012), 72–80.
17. Lewis, J.S., Zaveri, T.D., Crooks, C.P. 2nd, Keselowsky, B.G., Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials 33 (2012), 7221–7232.
18. Getts, D.R., Martin, A.J., McCarthy, D.P., Terry, R.L., Hunter, Z.N., Yap, W.T., Getts, M.T., Pleiss, M., Luo, X., King, N.J., Shea, L.D., Miller, S.D., Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30 (2012), 1217–1224.
19. Cardenas, M.E., Zhu, D., Heitman, J., Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr. Opin. Nephrol. Hypertens. 4 (1995), 472–477.
20. Ho, S., Clipstone, N., Timmermann, L., Northrop, J., Graef, I., Fiorentino, D., Nourse, J., Crabtree, G.R., The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 80 (1996), S40–S45.
21. Bachmann, M.F., Jennings, G.T., Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10 (2010), 787–796.
22. Maldonado, R.A., LaMothe, R.A., Ferrari, J.D., Zhang, A.H., Rossi, R.J., Kolte, P.N., Griset, A.P., O'Neil, C., Altreuter, D.H., Browning, E., Johnston, L., Farokhzad, O.C., Langer, R., Scott, D.W., von Andrian, U.H., Kishimoto, T.K., Polymeric synthetic NPs for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E156–65.
23. Yeste, A., Nadeau, M., Burns, E.J., Weiner, H.L., Quintana, F.J., Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 11270–11275.
24. Quintana, F.J., Basso, A.S., Iglesias, A.H., Korn, T., Farez, M.F., Bettelli, E., Caccamo, M., Oukka, M., Weiner, H.L., Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453 (2008), 65–71.
25. Tsai, S., Shameli, A., Yamanouchi, J., Clemente-Casares, X., Wang, J., Serra, P., Yang, Y., Medarova, Z., Moore, A., Santamaria, P., Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32 (2010), 568–580.
26. Clemente-Casares, X., Blanco, J., Ambalavanan, P., Yamanouchi, J., Singha, S., Fandos, C., Tsai, S., Wang, J., Garabatos, N., Izquierdo, C., Agrawal, S., Keough, M.B., Yong, V.W., James, E., Moore, A., Yang, Y., Stratmann, T., Serra, P., Santamaria, P., Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530 (2016), 434–440.
27. Singha, S., Shao, K., Yang, Y., Clemente-Casares, X., Sole, P., Clemente, A., Blanco, J., Dai, Q., Song, F., Liu, S.W., Yamanouchi, J., Umeshappa, C.S., Nanjundappa, R.H., Detampel, P., Amrein, M., Fandos, C., Tanguay, R., Newbigging, S., Serra, P., Khadra, A., et al. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. Nat. Nanotechnol., 2017.
28. McHugh, M.D., Park, J., Uhrich, R., Gao, W., Horwitz, D.A., Fahmy, T.M., Paracrine co-delivery of TGF-beta and IL-2 using CD4-targeted NPs for induction and maintenance of regulatory T cells. Biomaterials 59 (2015), 172–181.
29. Baumgart, D.C., Carding, S.R., Inflammatory bowel disease: cause and immunobiology. Lancet 369 (2007), 1627–1640.
30. Baumgart, D.C., Sandborn, W.J., Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369 (2007), 1641–1657.
31. Isaacs, K.L., Lewis, J.D., Sandborn, W.J., Sands, B.E., Targan, S.R., State of the art: IBD therapy and clinical trials in IBD. Inflamm. Bowel Dis. 11 (2005), S3–S12.
32. Date, A.A., Hanes, J., Ensign, L.M., NPs for oral delivery: design, evaluation and state-of-the-art. J. Control. Release 240 (2016), 504–526.
33. Coskun, M., Intestinal epithelium in inflammatory bowel disease. Front. Med., 1, 2014, 24.
34. Mahajan, N., Sakarkar, D., Manmode, A., Pathak, V., Ingole, R., Dewade, D., Biodegradable NPs for targeted delivery in treatment of ulcerative colitis. Adv. Sci. Lett. 4 (2011), 349–356.
35. Moulari, B., Pertuit, D., Pellequer, Y., Lamprecht, A., The targeting of surface modified silica NPs to inflamed tissue in experimental colitis. Biomaterials 29 (2008), 4554–4560.
36. Pertuit, D., Moulari, B., Betz, T., Nadaradjane, A., Neumann, D., Ismaili, L., Refouvelet, B., Pellequer, Y., Lamprecht, A., 5-amino salicylic acid bound NPs for the therapy of inflammatory bowel disease. J. Control. Release 123 (2007), 211–218.
37. Wilson, D.S., Dalmasso, G., Wang, L., Sitaraman, S.V., Merlin, D., Murthy, N., Orally delivered thioketal NPs loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9 (2010), 923–928.
38. Laroui, H., Theiss, A.L., Yan, Y., Dalmasso, G., Nguyen, H.T., Sitaraman, S.V., Merlin, D., Functional TNFalpha gene silencing mediated by polyethyleneimine/TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials 32 (2011), 1218–1228.
39. Bhavsar, M.D., Tiwari, S.B., Amiji, M.M., Formulation optimization for the NPs-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release 110 (2006), 422–430.
40. Kriegel, C., Attarwala, H., Amiji, M., Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv. Drug Deliv. Rev. 65 (2013), 891–901.
41. Bhavsar, M.D., Amiji, M.M., Gastrointestinal distribution and in vivo gene transfection studies with NPs-in-microsphere oral system (NiMOS). J. Control. Release 119 (2007), 339–348.
42. Bhavsar, M.D., Amiji, M.M., Development of novel biodegradable polymeric NPs-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech 9 (2008), 288–294.
43. Kriegel, C., Amiji, M., Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 150 (2011), 77–86.
44. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., NPs enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315 (2005), 196–202.
45. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., A pH-sensitive microsphere system for the colon delivery of tacrolimus containing NPs. J. Control. Release 104 (2005), 337–346.
46. Schmidt, C., Lautenschlaeger, C., Collnot, E.M., Schumann, M., Bojarski, C., Schulzke, J.D., Lehr, C.M., Stallmach, A., Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa–a first in vivo study in human patients. J. Control. Release 165 (2013), 139–145.
47. Lautenschlager, C., Schmidt, C., Lehr, C.M., Fischer, D., Stallmach, A., PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 85 (2013), 578–586.
48. Boehncke, W.H., Schon, M.P., Psoriasis. Lancet 386 (2015), 983–994.
49. Diani, M., Altomare, G., Reali, E., T cell responses in psoriasis and psoriatic arthritis. Autoimmun. Rev. 14 (2015), 286–292.
50. Chung, Y., Eder, L., Chandran, V., Gladman, D., Cardiovascular morbidity and mortality of cutaneous psoriasis (PsC) and psoriatic arthritis (PsA) are well documented, with increased risks of myocardial infarction, ischemic heart disease, and the metabolic syndrome in these patients. J. Rheumatol. 42 (2015), 1344–1345.
51. Golden, J.B., McCormick, T.S., Ward, N.L., IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine 62 (2013), 195–201.
52. Husted, J.A., Thavaneswaran, A., Chandran, V., Eder, L., Rosen, C.F., Cook, R.J., Gladman, D.D., Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res. 63 (2011), 1729–1735.
53. Benham, H., Norris, P., Goodall, J., Wechalekar, M.D., FitzGerald, O., Szentpetery, A., Smith, M., Thomas, R., Gaston, H., Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res. Ther., 15, 2013.
54. Laggner, U., Di Meglio, P., Perera, G.K., Hundhausen, C., Lacy, K.E., Ali, N., Smith, C.H., Hayday, A.C., Nickoloff, B.J., Nestle, F.O., Clinical relevance of pro-inflammatory skin homing CLA+ V gamma 9 V delta 2 T cells in psoriasis. Br. J. Dermatol., 164, 2011 907–907.
55. Laggner, U., Di Meglio, P., Perera, G.K., Hundhausen, C., Lacy, K.E., Ali, N., Smith, C.H., Hayday, A.C., Nickoloff, B.J., Nestle, F.O., Identification of a novel proinflammatory human skin-homing V gamma 9 V delta 2 T cell subset with a potential role in psoriasis. J. Immunol. 187 (2011), 2783–2793.
56. Baboota, S., Alam, M.S., Sharma, S., Sahni, J.K., Kumar, A., Ali, J., Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int. J. Pharm. Invest. 1 (2011), 139–147.
57. Badilli, U., Sen, T., Tarimci, N., Microparticulate based topical delivery system of clobetasol propionate. AAPS PharmSciTech 12 (2011), 949–957.
58. Cevc, G., Blume, G., Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. BBA–Biomembranes 1663 (2004), 61–73.
59. Korting, H.C., Zienicke, H., Schaferkorting, M., Braunfalco, O., Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis-vulgaris. Eur. J. Clin. Pharmacol. 39 (1990), 349–351.
60. Zhang, J., Smith, E., Percutaneous permeation of betamethasone 17-valerate incorporated in lipid NPs. J. Pharm. Sci. 100 (2011), 896–903.
61. Lin, Y.K., Huang, Z.R., Zhuo, R.Z., Fang, J.Y., Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomed. 5 (2010), 117–128.
62. Arora, R., Katiyar, S.S., Kushwah, V., Jain, S., Solid lipid NPs and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin. Drug Deliv. 14 (2017), 165–177.
63. Wan, T., Pan, W., Long, Y., Yu, K., Liu, S., Ruan, W., Pan, J., Qin, M., Wu, C., Xu, Y., Effects of NPs with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int. J. Nanomed. 12 (2017), 1485–1497.
64. Ali, M.F.M., Salah, M., Rafea, M., Saleh, N., Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med. Sci. Monit. 14 (2008), Pi66–Pi74.
65. Lakshmi, P.K., Devi, G.S., Bhaskaran, S., Sacchidanand, S., Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J. Dermatol. Venereol. Leprol. 73 (2007), 157–161.
66. Trotta, M., Peira, E., Carlotti, M.E., Gallarate, M., Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 270 (2004), 119–125.
67. Trotta, M., Peira, E., Debernardi, F., Gallarate, M., Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int. J. Pharm. 241 (2002), 319–327.
68. Harris, E.D. Jr., Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322 (1990), 1277–1289.
69. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001), 189–207.
70. Bernardi, A., Zilberstein, A.C.C.V., Jager, E., Campos, M.M., Morrone, F.B., Calixto, J.B., Pohlmann, A.R., Guterres, S.S., Battastini, A.M.O., Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br. J. Pharmacol. 158 (2009), 1104–1111.
71. Metselaar, J.M., Wauben, M.H.M., Wagenaar-Hilbers, J.P.A., Boerman, O.C., Storm, G., Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48 (2003), 2059–2066.
72. Kim, M.J., Park, J.S., Lee, S.J., Jang, J., Park, J.S., Back, S.H., Bahn, G., Park, J.H., Kang, Y.M., Kim, S.H., Kwon, I.C., Jo, D.G., Kim, K., Notch1 targeting siRNA delivery NPs for rheumatoid arthritis therapy. J. Control. Release 216 (2015), 140–148.
73. Lee, S.J., Lee, A., Hwang, S.R., Park, J.S., Jang, J., Huh, M.S., Jo, D.G., Yoon, S.Y., Byun, Y., Kim, S.H., Kwon, I.C., Youn, I., Kim, K., TNF-alpha gene silencing using polymerized siRNA/thiolated glycol chitosan NPs for rheumatoid arthritis. Mol. Ther. 22 (2014), 397–408.
74. Duan, J.L., Dong, J.L., Zhang, T.T., Su, Z.Y., Ding, J., Zhang, Y., Mao, X.H., Polyethyleneimine-functionalized iron oxide NPs for systemic siRNA delivery in experimental arthritis. Nanomed.: Nanotechnol. Biol. Med. 9 (2014), 789–801.
75. Lee, S.M., Kim, H.J., Ha, Y.J., Park, Y.N., Lee, S.K., Park, Y.B., Yoo, K.H., Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional NPs. ACS Nano 7 (2013), 50–57.
76. Nogueira, E., Gomes, A.C., Preto, A., Cavaco-Paulo, A., Folate-targeted NPs for rheumatoid arthritis therapy. Nanomed.–Nanotechnol. 12 (2016), 1113–1126.
77. Thomas, T.P., Goonewardena, S.N., Majoros, I.J., Kotlyar, A., Cao, Z.Y., Leroueil, P.R., Baker, J.R., Folate-targeted NPs show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum. 63 (2011), 2671–2680.
78. Fiehn, C., Neumann, E., Wunder, A., Krienke, S., Gay, S., Muller-Ladner, U., Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann. Rheum. Dis. 63 (2004), 884–886.
79. Thao, L.Q., Byeon, H.J., Lee, C., Lee, S., Lee, E.S., Choi, H.G., Park, E.S., Youn, Y.S., Pharmaceutical potential of tacrolimus-loaded albumin NPs having targetability to rheumatoid arthritis tissues. Int. J. Pharm. 497 (2016), 268–276.